Dr Lal Pathlabs Ltd

BSE :539524 NSE :LALPATHLAB Sector : Healthc..
2,399.40
Change: -88.60(-3.56%)
Buy Sell SIP
52 week Low
2,165.80
52 week High
3,653.95
Day low
2,376.10
Day high
2,519
Prev Close
2,488.00
Open
2,489.75
6M return
-27.35%
1Y return
6.03%
MCap(Rs. in Cr.)
20,720.72
Total Volume
4,16,611
Face Value : 10
Listed Since 23 Dec 2015
PE Ratio

Is the price-earnings ratio for valuing a company that measures its current share price relative to its earnings per share.

P/E RATIO
49.70116
EPS

The earnings per share ratio is a portion of company's net profit allocated for each outstanding share. It is calculated by deducting preferred stock divided from the net income of the company divided by the number of outstanding shares.

EPS
49.86
PRICE/BOOK

Price-to-book ratio is used to compared the company's current market price with its book value.

PRICE/BOOK
10.02
Deliverable

These are the acutal number of shares that are traded on delivery based, meaning transfered from one person to another during the day's trade.

DELIVERABLES
69.82%
DIV YIELD.(%)

Dividend Yield measures the quantum of cash dividends paid to shareholders in a financial year relative to the market value of the per share.

DIV YIELD.(%)
0.73

Company Details

Check out the key parameters of the company to understand the financial health and stock performance

Key Level

Resistance 1
2558.83
Resistance 2
2629.67
Support 1
2413.58
Support 2
2339.17

Moving Average

20 Days
2475.81
50 Days
2632.00
100 Days
2822.59
200 Days
2987.95
Growth in 3 years

Sales
6.67%

Sales Industry Avg
4.63%

PAT
3.43%

PAT Industry Avg
6.30%

Dec 2024
( in Cr.)		Sep 2024
( in Cr.)		Jun 2024
( in Cr.)		Mar 2024
( in Cr.)		FY 2024
( in Cr.)
Sales596.70660.20601.90545.402,226.64
Gross Profit173.80218.40184.60156.50649.05
Operating Profit00000
Profit Before Tax137.60179.20152.60118.40505.45
Tax39.5048.4044.8032.60143.16
Profit After Tax98.10130.80107.8085.80362.29
Growth in 3 years

Total Asset Growth
3.03%

Total Liabilities growth
3.03%

Reserves Change
24.51%

Mar 2024
( in Cr.) 		Mar 2023
( in Cr.) 		Mar 2022
( in Cr.) 		Mar 2021
( in Cr.) 		Mar 2020
( in Cr.)
Share Capital83.4883.3783.4883.4683.35
Reserves And Surplus1,765.811,582.931,418.261,161.71949.47
Investments113.78149.9465.4659.30164.28
Total Debt246.93419.50532.44150.3792.97
Total Liabilities2,132.302,119.052,069.641,426.501,147.01
Total Assets2,132.302,119.032,069.631,426.491,147.01
60%
2023
120%
60%
60%
60%
2024 2025
60%
2026


Relative to Sensex rtn in 3 year
-120.13%

Relative to Nifty rtn in 3 year
-118.67%



1 Year (%)2 Year (%)3 Year (%)
Dr Lal Pathlabs633-6
Bse Sensex33232
Nifty 5043735
Nifty 50044844

Peer Companies

A quick glance on how stocks from the same sector have performed along with some key parameters

Dr Lal Pathlabs
2,399.40
Change: -88.60 (-3.56%)
1 Year return
6.03%
Risk (Std Dev)
0.09%
PE Ratio
49.70116
MCap( in Cr.)
20,720.72
BUY SELL
Max Healthcare
1,083.60
Change: -45.80 (-4.06%)
1 Year return
32.16%
Risk (Std Dev)
0.10%
PE Ratio
100.52246
MCap( in Cr.)
1,06,639.12
BUY SELL
Apollo Hospitals
6,632.30
Change: 140.25 (2.16%)
1 Year return
4.33%
Risk (Std Dev)
0.07%
PE Ratio
72.67669
MCap( in Cr.)
95,130.80
BUY SELL
Fortis Health.
688.65
Change: 16.85 (2.51%)
1 Year return
63.89%
Risk (Std Dev)
0.07%
PE Ratio
66.84211
MCap( in Cr.)
52,722.50
BUY SELL
Narayana Hrudaya
1,676.80
Change: 3.40 (0.20%)
1 Year return
30.61%
Risk (Std Dev)
0.06%
PE Ratio
44.10300
MCap( in Cr.)
34,578.87
BUY SELL
View More

Return Calculator

This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.

 

If I had made
investment of  
in
Months Ago
My investment would be worth 1,06,034.40 with a Gain of 6.03%

Our Research Reports

Stocks and sector-wise Research Reports by HDFC securities help you analyse, understand and take a informed investment decision.

Institutional Reports 17 Mar 2025 6:44 AM
Dr. Lal Pathlabs: Focus on volume-led growth and margin. Maintain ADD
Dr. Lal Pathlabs (DLPL) is expected to sustain steady revenue growth, led by (1) patient and sample volume growth, with no price test increase in the near term, (2) increasing traction from its welln..
Institutional Reports 31 Jan 2025 7:13 AM
HSIE Results Daily: Larsen & Toubro, Shree Cement, SRF, Hitachi Energy, Voltas, Astral, Dr. Lal Pathlabs, Navin Fluorine International, Clean Science and Technology, Aavas Financiers, Quess Corp
Larsen & Toubro: Larsen & Toubro’s (LT) revenue/EBITDA/APAT came in at INR 646.7bn/62.5bn/33.6bn, missing estimates by 2.3%/10.7%/10.8%. P&M margins stood at 7.6% (flat YoY), and LT retained its guid..
Institutional Reports 14 Jan 2025 1:51 PM
Pharma and Healthcare (Q3FY25E): Growth momentum, margin visibility stay intact
The India Pharma & Healthcare sector is expected to see steady growth in Q3FY25E. We project sales/EBITDA growth of 11%/13% YoY for our coverage universe. Our assumptions are: (1) pharma coverage wil..
View More

Corporate Action

Find out the historical dividend payout and other corporate actions including bonus, stock split and rights issue etc.

D D
2023
D
D
D
D
2024
D
2025

News

Stay tuned to the latest developments and happenings in the company.

Dr Lal Pathlabs allots 4,000 equity shares under ESOP

Dr Lal Pathlabs has allotted 4,000 equity shares under ESOP on 18 February 2025. With this allotment, the paid up equity share capital has increased t....

18 Feb 2025 18:20

Dr Lal Pathlabs consolidated net profit rises 18.94% in the December 2024 quarter

Net profit of Dr Lal Pathlabs rose 18.94% to Rs 96.70 crore in the quarter ended December 2024 as against Rs 81.30 crore during the previous quarter e....

30 Jan 2025 14:39

Board of Dr. Lal PathLabs recommends Third Interim dividend

Dr. Lal PathLabs announced that the Board of Directors of the Company at its meeting held on 30 January 2025, inter alia, have recommended the Third I....

30 Jan 2025 14:09

Dr. Lal PathLabs to conduct board meeting

Dr. Lal PathLabs will hold a meeting of the Board of Directors of the Company on 30 January 2025.Powered by Capital Market - Live News</b....

23 Jan 2025 17:28

Dr Lal Pathlabs consolidated net profit rises 18.21% in the September 2024 quarter

Net profit of Dr Lal Pathlabs rose 18.21% to Rs 129.20 crore in the quarter ended September 2024 as against Rs 109.30 crore during the previous quarte....

23 Oct 2024 17:47

Dr Lal Pathlabs consolidated net profit rises 28.81% in the June 2024 quarter

Net profit of Dr Lal Pathlabs rose 28.81% to Rs 106.40 crore in the quarter ended June 2024 as against Rs 82.60 crore during the previous quarter ende....

07 Aug 2024 16:26

View More
Subscribe for our
newsletter
Open Account Now